Home › Companies › QUIT
Achieve Life Sciences
Market cap $673M 110.0M shares (10-Q, Nov 10, 2026) × $6.12 close Nov 17, 2026
Most recent annual filing: 2026-03-24
Q3Q4Q1 ’27Q2Q3Q4Q1 ’28Q2
- Cytisinicline smoking cessation NDA filing4Q 2026Cytisinicline smoking cessation NDA filing, 4Q 2026, major
- Sopharma arbitration corporate update4Q 2026/1Q 2027Sopharma arbitration corporate update, 4Q 2026/1Q 2027, material
- Cytisinicline smoking cessation FDA approvallate 2Q 2027Cytisinicline smoking cessation FDA approval, late 2Q 2027, thesis-defining
- Cytisinicline vaping cessation Ph3 start~Oct 2027Cytisinicline vaping cessation Ph3 start, ~Oct 2027, notable
- CNPV corporate update~Oct 2027CNPV corporate update, ~Oct 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a
six-month window. Deeper blue means more of the thesis rides on the event; it is not a
view on the stock.
Pipeline (2 active programs)
Capital (as filed)
- Cash
- $59.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $142M Sep 30, 2026
- Operating cash flow
- −$8.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $202M cash per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Achieve Life Sciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-08-12 Watch Achieve Life Sciences (ACHV) — Scientific Deep Dive for Cytisinicline and Pipeline Products The clinical package is legitimately good and the CRL was fixable, but two named questions must resolve before the stock is investable: whether the Sopharma arbitration disturbs the Adare-based resubmission, and whether FDA grants five-year NCE exclusivity to a molecule sold in Bulgaria since 1964.
- 2026-08-15 Watch UPDATE: Achieve Life Sciences (ACHV) - The $150M Insurance Policy The ATM facility bridges the structural dilution gap and de-links launch spending from the approval-triggered warrant clock, but the Sopharma arbitration and NCE exclusivity question remain unresolved, keeping the stock uninvestable.
- 2026-11-11 Watch UPDATE: AchieveRx (QUIT, formerly ACHV) - The Voucher Expires on Paper The resubmission remains on track but the CNPV will expire unused, eliminating the vaping program's only accelerant; the two core unresolved questions (Sopharma arbitration, NCE exclusivity) remain open.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Based on our current development timeline, which includes completion of our Phase 3 ORCA-V2 trial, we do not expect to submit a supplemental NDA for vaping cessation before the CNPV expires in October 2027.”
matched to Cytisinicline (vaping cessation, ORCA-V2) · trial initiation
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (26)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first.
Releases captured from Aug 11, 2026;
filings from March 2026.
Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseAchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1
- Nov 10, 202610-QQuarterly report
- Nov 9, 2026ReleaseAchieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
- Oct 21, 2026ReleaseAchieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026BD extracted 1 program update from this document → QUIT pipeline
- Oct 7, 2026ReleaseAchieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- Oct 1, 2026ReleaseAchieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
- Oct 1, 20268-KCurrent report: officer / director change
- Sep 28, 2026ReleaseAchieve Life Sciences to Present 52-Week Cytisinicline Efficacy Data for Smoking and E-Cigarette Cessation at CHEST 2026BD extracted 1 program update from this document → QUIT pipeline
- Aug 14, 20268-KCurrent report: other events
- Aug 14, 2026424B5Prospectus supplement (offering)
- Aug 11, 2026ReleaseAchieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jul 6, 20268-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- Jun 8, 2026DEF 14AProxy statement
- Jun 2, 20268-KCurrent report: officer / director change
- May 12, 2026S-3Shelf registration
- May 12, 20268-KCurrent report: results of operations, officer / director change · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 30, 202610-K/AAnnual report (amended)
- Apr 27, 2026SCHEDULE 13DActivist / >5% holder (13D)
- Apr 24, 2026SCHEDULE 13DActivist / >5% holder (13D)
- Apr 16, 20268-KCurrent report: material agreement, unregistered sale of equity, officer / director change · EX-99.1
- Mar 24, 20268-KCurrent report: results of operations · EX-99.1
- Mar 24, 202610-KAnnual report
21 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 17, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 28, 2026SCHEDULE 13G/A13G amendment
- Jul 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 8, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jun 8, 2026ARSAnnual report to shareholders
- May 29, 2026PRE 14APRE 14A
- May 21, 2026EFFECTRegistration effective
- May 19, 2026CORRESPCORRESP
- May 18, 2026UPLOADUPLOAD
- May 12, 2026S-8Employee plan registration
- May 7, 2026SCHEDULE 13G/A13G amendment
- Apr 24, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 24, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 24, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 16, 2026S-8Employee plan registration
- Mar 24, 2026S-8Employee plan registration